Literature DB >> 25179168

Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding.

Dominique Thabut1, Marika Rudler, Nina Dib, Nicolas Carbonell, Philippe Mathurin, Faouzi Saliba, Alain Mallet, Julien Massard, Brigitte Bernard-Chabert, Frederic Oberti, Paul Cales, Jean-Louis Golmard, Christophe Bureau.   

Abstract

UNLABELLED: The criteria for defining failure to control bleeding in cirrhosis patients were introduced at the Baveno II/III meetings and were widely used as endpoints in clinical trials. Because they lacked specificity, the Baveno IV criteria were proposed in 2005 and slightly modified in 2010 (Baveno V). These criteria included a new index for patients undergoing transfusion, called adjusted-blood-requirement-index (ABRI=number of blood units/(final-initial hematocrit+0.01)), with a cutoff value of 0.75. In this multicenter prospective study, we sought to 1) validate the Baveno IV/V criteria; 2) compare them to the Baveno II/III criteria; 3) assess ABRI performance using a standardized calculation. The key inclusion criteria were: 1) variceal bleeding; 2) cirrhosis; 3) no need to modify the transfusion policy. The patients were classified according to the Baveno IV, V, and II/III criteria. The gold standard for failure during a 5-day period was the clinical judgment of three independent experts, blinded to the Baveno assessments. A total of 249 patients were included. The experts' agreement in clinical judgment of the failure was 80%. Failure occurred in 20.5% of patients; the c-statistics were 0.72 versus 0.64 and 0.65 for Baveno IV versus Baveno II/III and Baveno V criteria (P=0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival.
CONCLUSION: The Baveno IV criteria demonstrated a higher accuracy than the Baveno II/III and Baveno V criteria for assessing failure to control bleeding and predicted survival independently. Together, our results show that ABRI is not a useful metric, and the Baveno IV criteria should replace the Baveno II/III criteria.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25179168     DOI: 10.1002/hep.27407

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

Review 1.  Management of Refractory Variceal Bleed in Cirrhosis.

Authors:  Gajanan A Rodge; Usha Goenka; Mahesh K Goenka
Journal:  J Clin Exp Hepatol       Date:  2021-09-04

2.  U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.

Authors:  Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; David Patch; Charles Millson; Homoyon Mehrzad; Andrew Austin; James W Ferguson; Simon P Olliff; Mark Hudson; John M Christie
Journal:  Gut       Date:  2015-04-17       Impact factor: 23.059

3.  Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States.

Authors:  Adeyinka Charles Adejumo; Gbeminiyi Olanrewaju Samuel; Oluwole Muyiwa Adegbala; Kelechi Lauretta Adejumo; Ogooluwa Ojelabi; Olalekan Akanbi; Olumuyiwa Akinbolaji Ogundipe; Lydie Pani
Journal:  Ann Gastroenterol       Date:  2019-07-17

4.  TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience.

Authors:  Huzheng Yan; Zhenkang Qiu; Zhanwang Xiang; Mingsheng Huang; Fei Gao; Kai Feng
Journal:  Cancer Imaging       Date:  2022-02-19       Impact factor: 3.909

5.  Clinical Factors Associated with Mortality in Cirrhotic Patients Presenting with Upper Gastrointestinal Bleeding.

Authors:  Kirles Bishay; Parul Tandon; Stacey Fisher; Dominique Yelle; Ian Carrigan; Krista Wooller; Erin Kelly
Journal:  J Can Assoc Gastroenterol       Date:  2019-03-10

6.  Prior Toxoplasma Gondii Infection Ameliorates Liver Fibrosis Induced by Schistosoma Japonicum through Inhibiting Th2 Response and Improving Balance of Intestinal Flora in Mice.

Authors:  Fei Xu; Ruitang Cheng; Sunhan Miao; Yuwei Zhu; Ze Sun; Liying Qiu; Junqi Yang; Yonghua Zhou
Journal:  Int J Mol Sci       Date:  2020-04-14       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.